Feature

Early Findings From First Human Study of In Vivo CAR T in Myeloma

The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration...

Share

Encouraging results from the first-in-human trial of in vivo CAR T-cell therapy KLN-1010 for multiple myeloma reflect promising safety and effectiveness, as reported by Dr. Phoebe Joy Ho from the University of Sydney at the 2025 ASH Annual Meeting. This innovative therapy aims to simplify CAR T administration by removing the need for preconditioning lymphodepletion and manufacturing, with all four participants achieving measurable residual disease negativity by month one. Early assessments show a noteworthy persistence of CAR T cells, with manageable adverse effects, positioning this off-the-shelf solution as a potential game-changer for myeloma treatment.

Original Source(s)

Early Findings From First Human Study of In Vivo CAR T in Myeloma

  • by Caroline Helwick

  • March 20, 2026

Related Content

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling

  • March 18, 2026

  • 9 min
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine.  

Register Today for Roswell Park’s Upstate New York Hematology & Hematologic Oncology Conference

Register for the Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual meeting, taking place on April 25-26 in Buffalo, NY.

  • by

  • March 13, 2026

  • 1 min